Search - tctmd.com

Displaying 1 - 20 of 115

Sort: Relevancy | Date

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

Presentation TCT 2025

TCT 900: Comparison of Drug-Coated Balloons and The Bioadaptor in Treatment of De Novo Coronary Lesions: A 2-Year Nationwide Analysis from SWEDEHEART

Presenter: David Erlinge

October 28, 2025

Presentation TCT 2025

Long Term Clinical Outcomes in Patients Treated with the Bioadaptor Compared with a Contemporary Drug Eluting Stent: The INFINITY-SWEDEHEART Randomized Trial

Presenter: David Erlinge

October 27, 2025

Presentation TCT 2025

INFINITY-SWEDEHEART-RCT 1 Year Clinical Outcomes

Presenter: David Erlinge

October 26, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News ESC 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

Todd Neale

September 03, 2025

Presentation ESC 2025

Helicobacter Pylori Screening after Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI-SWEDEHEART Trial

Presenter: Robin Hofmann

August 31, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

Presentation TCT 2024

Overview of Latest Clinical Evidence

Presenter: David Erlinge

October 30, 2024

Presentation TCT 2024

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary Drug Eluting Stent From the INFINITY-SWEDEHEART

Presenter: David Erlinge

October 28, 2024

Presentation TCT 2024

TCT 290: Survival After PCI or CABG in Patients With NSTEMI and Left Main Disease: A Report From the SWEDEHEART Registry

Presenter: Elmir Omerovic

October 28, 2024

Presentation TCT 2024

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary DES From the INFINITY-SWEDEHEART Randomized Clinical Trial

Presenter: David Erlinge

October 28, 2024

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

Presentation ESC 2024

INFINITY-SWEDEHEART: Percutaneous coronary intervention with a Bioadaptor compared to a contemporary Drug-eluting Stent (DES) in a large broad clinical population

Presenter: David Erlinge

September 02, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Opinion Editor's Corner

What’s Going to Be Hot at ESC 2024

Shelley Wood

August 23, 2024

Advertisement

December 2025 Dispatch for the CV Team

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

TCT 900: Comparison of Drug-Coated Balloons and The Bioadaptor in Treatment of De Novo Coronary Lesions: A 2-Year Nationwide Analysis from SWEDEHEART

Long Term Clinical Outcomes in Patients Treated with the Bioadaptor Compared with a Contemporary Drug Eluting Stent: The INFINITY-SWEDEHEART Randomized Trial

INFINITY-SWEDEHEART-RCT 1 Year Clinical Outcomes

What’s Going to Be Hot at TCT 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

Helicobacter Pylori Screening after Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI-SWEDEHEART Trial

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Overview of Latest Clinical Evidence

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary Drug Eluting Stent From the INFINITY-SWEDEHEART

TCT 290: Survival After PCI or CABG in Patients With NSTEMI and Left Main Disease: A Report From the SWEDEHEART Registry

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary DES From the INFINITY-SWEDEHEART Randomized Clinical Trial

What’s Going to Be Big at TCT 2024?

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

INFINITY-SWEDEHEART: Percutaneous coronary intervention with a Bioadaptor compared to a contemporary Drug-eluting Stent (DES) in a large broad clinical population

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

What’s Going to Be Hot at ESC 2024

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content